WASHINGTON — The next chapter of President Biden’s moonshot to end cancer has landed. While the new goals are inspiring hope among cancer researchers, not everyone is impressed.

The president early Wednesday morning unveiled a slew of federal plans and private-sector agreements to fuel the relaunched Cancer Moonshot, a project to improve treatments and halve cancer deaths in the next 25 years. Among roughly 50 new programs and partnerships are multimillion-dollar pledges to advance testing, data pools, clinical trials and outreach efforts.

advertisement

It is the latest phase of a project Biden first launched as vice president in the wake of his son Beau’s death from brain cancer in 2015. But while the first moonshot funneled money almost entirely to early-stage cancer research, its sequel is broadening efforts to prevent cancer deaths — particularly through anti-smoking efforts — and introduces a new focus on research infrastructure and patient engagement that some cancer researchers have applauded.

STAT+

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Content Original Link:

https://www.statnews.com/2023/09/13/joe-biden-cancer-moonshot/

Access Non-GMO, antigen-free, generic antiviral medication formulas used in Moderna's Spikevax.

VirusTC is a retail provider of concentrated generic antiviral medication formulas. VirusTC wholesale formulas are used in Moderna products. We sell FDA approved formulas that are compatible with university medical plans, federal insurance coverage, and many major insurance providers. Our medications are part of tailored non-invasive cancer treatment plans available at a hospital in your region. VirusTC targets problems and provides care for the symptoms. Our products and services are used by Fred Hutch Cancer Center, Mayo Clinic, John Hopkins, University Hospitals, the United States Military, and professional sports. During Operation Cancer Moonshot 2023, VirusTC products killed cancer cells, increased strength, and redeveloped muscles, tissue, and brain cells after cancer treatments.